



The 2<sup>nd</sup> World Congress on  
**Clinical Trials in Diabetes**  
27-28 November 2017 | Berlin, Germany

**The 2<sup>nd</sup> World Congress on Clinical Trials in Diabetes (WCTD2017)**

**Summary**

The 2nd World Congress on Clinical Trials in Diabetes that was conducted in collaboration with the D-Cure Foundation of Israel, took place on 27-28 November 2017 in Berlin, Germany.

This second congress, welcomed over 100 delegates from 37 countries. The delegates represented professionals ranging physicians, health professionals and researchers, as well as representatives of the pharmaceutical industry. WCTD2017 addressed clinical trials in diabetes, to enhance drug and device development and promote innovative therapeutic regimens and modes.

The program included lectures on the following topics:

- Innovation in diabetes and high impact clinical trials in 2017 – in these lectures, issues **Lessons from High Impact Clinical Trials in 2017** and **Innovation in Diabetes – What's Ahead** were presented and discussed by Ralph DeFronzo (USA) and Francesco Giorgino (Italy)
- Clinical management guidelines in diabetes – Presented by Philip Home (UK) discussed good and bad evidence in a very informative lecture.
- Regulatory trends – the EMA and FDA perspectives was presented by representatives from the EU (**EMA Perspective** - Giuseppe Rosano (UK)) and the USA (**US and FDA Perspective** - Zan Fleming (USA)). The main issue raised was the definition of innovative endpoints, and the contribution of new technologies to the design of trials in diabetes.
- Cardiovascular outcomes presentations were presented in 2 sessions as well as in the oral presentation abstract session. Very interesting lectures were presented by John Lachin (USA), Neda Rasouli (USA), Antonio Ceriello (Italy) and Oliver Schnell (Germany) amongst others.
  - Cardiovascular Outcome Studies Part 1: What can we Learn from Retrospective Data
  - Cardiovascular Outcome Studies Part 2: Design, Interpretation and Translation
- Advantages and shortfalls of big data – was presented through the experience of Ran Goshen (Israel).

In addition to the above-mentioned topics, a designated session for oral presentations of participants in the congress provided insight in to new research and allowed up and coming scientists to present at this unique Congress.